Chiron Wins Vaccine Approval

Chiron ( CHIR ) Wednesday received a license from New Zealand authorities for its meningococcal B vaccine.

The California-based biotech firm developed the MeNZB vaccine with health officials in New Zealand as well as Norway.

Chiron said the vaccine was developed specifically to protect against the meningococcal B strain responsible for a 13-year epidemic in New Zealand, which has stricken more than 5,000 people and left hundreds dead or permanently disabled.

Meningococcal disease results from infection caused by the bacterium Neisseria meningitidis, known as meningococcus. It usually affects the membranes around the brain and spinal cord or the bloodstream and can result in brain damage, blindness, deafness, limb amputations and death.

Chiron began with project with the New Zealand government in 2001.

More from Stocks

Quick Read: 3 Things for Investors to Know Before Wednesday's Trading Session

Quick Read: 3 Things for Investors to Know Before Wednesday's Trading Session

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Micron Shares Soar; Chipmaker Is 'Managing for Profitability' Now, Says Analyst

Micron Shares Soar; Chipmaker Is 'Managing for Profitability' Now, Says Analyst

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline